The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Mesalamine 800 mg delayed-release tablets, referencing ASACOL HD ® - Lenalidomide capsules, referencing REVLIMID ® BRIDGEWATER, N.J., February 19, 2025--(BUSINESS WIRE)--Amnea ...

Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Amneal Pharmaceuticals (AMRX) reports results for the quarter ended December 2024. While this widely-known consensus ...

The FDA has approved a generic version of lenalidomide, a drug used to treat multiple myeloma and myelodysplastic syndromes, with availability set for Jan. 31, 2026.

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with ...

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation ("Twist" or the "Company"), a core mid-cap growth and value equity company in the life sciences segment of the health ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

First Bancshares, Inc. (OTCQX: FBSI), the holding company for Stockmens Bank (“Bank”), Colorado Springs, Colorado, announced today that its Board of Directors declared an annual cash dividend of $0.40 ...

— In a speech heavy on highlighting the need for certainty across American industry, Timmons also called for Washington to “move faster” on rolling back “costly, burdensome” regulations and pushing ...